DailyFinance EWING, N.J.--(BUSINESS WIRE)-- Antares Pharma, Inc. (NAS: ATRS) today announced subcutaneous methotrexate delivered with a new, self-administration device demonstrates bioavailability that is significantly greater than oral methotrexate in the ...
Monthly Prescribing Reference Among patients continuing treatment with Simponi 50mg in combination with methotrexate or other disease-modifying antirheumatic drugs (DMARDs) through five years, between 60% and 85% of patients experienced at least a 20% improvement in American ...
Zenopa Dr John Medich, divisional vice-president for immunology clinical development and global pharmaceutical research and development at AbbVie, said: "With Concerto, ...
MarketWatch MADRID, June 13, 2013 /PRNewswire via COMTEX/ -- AbbVie (NYSE:ABBV) today announced the results from the CONCERTO trial, the first randomized, controlled trial assessing different predefined doses of methotrexate (MTX) in combination with ...
Fort Mills Times Antares Pharma, Inc. (NASDAQ: ATRS) today announced subcutaneous methotrexate delivered with a new, self-administration device demonstrates bioavailability that is significantly greater than oral methotrexate in the treatment of adults with rheumatoid ... and more »
pharmabiz.com AbbVie has presented results from the CONCERTO trial, the first randomized, controlled trial assessing different predefined doses of methotrexate (MTX) in combination with HUMIRA (adalimumab) for the treatment of moderate to severe rheumatoid arthritis ...
Doctor Tipster The study that showed similarity between ADA and ABA is called AMPLE and was a phase IIIb clinical trial that included 646 biologic-naïve patients with rh...
Monthly Prescribing Reference Bristol-Myers Squibb announced the results of Year 2 data from its Phase 3b study AMPLE (Abatacept Versus Adalimumab Comparison Biologic-Na...
WebMD TUESDAY, June 11 (HealthDay News) -- Newer, costlier treatment for rheumatoid arthritis appears no better than an older, less-expensive regimen for people who don't respond to the first-line drug methotrexate , a new study suggests. "Newer isn't always ...
